DR. MICHAEL J HOLTZMAN, MD
Osteopathic Medicine at Euclid Ave, Saint Louis, MO
License number
Missouri R2H44
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
660 S Euclid Ave, Saint Louis, MO 63110
Phone
(314) 362-8983
(314) 362-8987 (Fax)
(314) 362-8987 (Fax)
Personal information
See more information about MICHAEL J HOLTZMAN at radaris.comName
Address
Phone
14 Brentmoor Park, Saint Louis, MO 63105
14 Brentmoor Park, Clayton, MO 63105
Professional information
Michael Jay Holtzman, Saint Louis MO
Specialties:
Internal Medicine, Pulmonary Disease, Cardiology, Cardiovascular Disease, Family Medicine, General Practice
Work:
Washington University at St. Louis
660 S Euclid Ave, Saint Louis, MO 63110
660 S Euclid Ave, Saint Louis, MO 63110
Education:
Northwestern University (1975)
Dr. Michael J Holtzman, Saint Louis MO - MD (Doctor of Medicine)
Specialties:
Pulmonology
Address:
WA Univ Schl Mdcn Plmnry Mdcn
660 S Euclid Ave SUITE 8052, Saint Louis 63110
(314) 454-8764 (Phone)
660 S Euclid Ave SUITE 8052, Saint Louis 63110
(314) 454-8764 (Phone)
Certifications:
Internal Medicine, 1978, Pulmonary Disease, 1980
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
WA Univ Schl Mdcn Plmnry Mdcn
660 S Euclid Ave SUITE 8052, Saint Louis 63110
Barnes Jewish Hospital
1 Barnes Jewish Hospital Plz, Saint Louis 63110
660 S Euclid Ave SUITE 8052, Saint Louis 63110
Barnes Jewish Hospital
1 Barnes Jewish Hospital Plz, Saint Louis 63110
Education:
Medical School
Northwestern Center Feinberg School of Medicine
Graduated: 1975
Duke Med Ctr
U Calif
Northwestern Center Feinberg School of Medicine
Graduated: 1975
Duke Med Ctr
U Calif
Compositions And Methods For Treatment Of Airway Hypersecretion
US Patent:
2007008, Apr 12, 2007
Filed:
Oct 10, 2006
Appl. No.:
11/545701
Inventors:
Michael Holtzman - Clayton MO, US
Assignee:
Washington University - St. Louis MO
International Classification:
A61K 48/00, A61K 39/395
US Classification:
514044000, 424145100
Abstract:
The invention relates generally to the field of treating pulmonary diseases. More specifically, the invention relates to the treatment of airway hypersecretion by the administration of an inhibitor of the epidermal growth factor receptor (EGFR) signaling pathway in combination with an inhibitor of the interleukin-13 (IL-13) signaling pathway, as well as compositions thereof.